Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.


Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), affecting ∼50% of patients, and both renal disease and treatment-related toxicity contribute to significant morbidity and mortality. Although our understanding of the aetiopathogenesis of LN is improving, treatment still remains a challenge, with the… (More)
DOI: 10.1093/ndt/gfw288


  • Blog articles referencing this paper

  • Presentations referencing similar topics